New Drug Targets
The world's biological research drugs have always paid the most attention to anti-cancer drugs, and the next step is to gradually turn to neurological drugs. Currently, the most influential drugs are anti-coronavirus pneumonia drugs. Jian Gang has achieved the following achievements in these areas:
(1) Treatment of brain dysfunction-Aescin:
Aescin has undergone Phase II and III clinical trials in Italy, and Jian Gang now has better aescin drug results. Aescin is undergoing phase II and phase III clinical trials for the coronavirus COVID-19 in Italy. According to the preliminary research of the medical team, the saponins can protect the lungs and reduce the damage of the virus to the lungs of patients. The clinical safety and efficacy of oral and injection treatments are respectively. Aescin is a traditional European botanical medicine and the third largest botanical medicine in the German market. It has been widely used in the treatment of blood diseases, vascular swelling, rheumatism, and anti-swelling for decades. There are hundreds of related products, but it has The side effects of hemolysis and the history of use are both troublesome between hemolysis and curative effect.
Jian Gang has been researching the aescin family for many years, and successfully transformed the European aescinate to maintain the curative effect and eliminate the side effects of hemolysis, and obtained a patent. The clinical practice of aescin for the coronary disease COVID-19 in foreign countries is a sign that our research direction is correct. It is a good time to develop non-hemolytic saponins to treat coronaviruses based on our experience. This project can develop saponin drugs from natural and optimized saponins that can restrain coronavirus from invading cells.
(2) Anti-cancer and anti-virus-Chonglou
According to Clause 18A listed in Hong Kong, Dangjiangang has drug research into phase II, and the financing amount, technology patents and other evaluations reach or exceed HK$1.5 billion, it can apply for listing in Hong Kong; before a drug enters phase II clinical trials, its estimated market value has been Reached RMB 1.475 billion. Jian Gang has appointed Xu Lin Law Firm as its listing agent, and relevant procedures are already on the agenda.
(3) Treatment of neurological diseases
Health Kong Canada will select the most suitable neurological drug development.